ReviewCurrent opinion in pharmacology2013
Tumour heterogeneity and immune-modulation.
Review in Current opinion in pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).Annals of oncology : official journal of the European Society for Medical Oncology · 2016Trial
- Patient-Derived Organoid-Based CRISPR Screens in Cancer Research: Applications, Advances, and Challenges.Cancer medicine · 2026Review
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular-Orthomolecular Strategies.Cancers · 2026Review
- Therapeutic antibodies for the prevention and treatment of cancer.Journal of biomedical science · 2024Review
- Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.Current oncology (Toronto, Ont.) · 2023Review
- BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.Cancer immunology, immunotherapy : CII · 2023Article
- Multi-targeted immunotherapeutics to treat B cell malignancies.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Recent advances in micro-/nanostructure array integrated microfluidic devices for efficient separation of circulating tumor cells.RSC advances · 2022Review
- Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions.Antibodies (Basel, Switzerland) · 2022Review
- Clinical Translation of Neutrophil Imaging and Its Role in Cancer.Molecular imaging and biology · 2022Review
- LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion.Nature genetics · 2022Article
- Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy.Frontiers in immunology · 2022Article
- Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach.Cancers · 2018Review
- Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.Frontiers in immunology · 2017Review
- Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.Immunity · 2016Article
- Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer.Cancer discovery · 2016Review
- Translational implications of tumor heterogeneity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
- Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patients.Biochemical Society transactions · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recent advances in sequencing technologies have revealed extensive intratumour heterogeneity (ITH) both within individual tumours and between primary and metastatic tumours for different cancer types. Such genetic diversity may have clinical implications for both cancer diagnosis and treatment with increasing evidence linking ITH and therapeutic resistance. Nonetheless, whilst limiting the activity of targeted agents, tumour genetic heterogeneity may provide a new therapeutic opportunity through generation of neo-antigens that could be recognised and targeted by the patient's own immune system in response to immune-modulatory therapies. Longitudinal genomic studies assessing tumour clonal architecture and its correlation with the underlying immune response to cancer in each particular patient are needed to follow tumour evolutionary dynamics over time and through therapy, in order to further understand the mechanisms behind drug resistance and to inform the development of new combinatorial therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.